Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells

The multikinase inhibitor sorafenib is the only standard first-line therapy for hepatocellular carcinoma (HCC). Here, we report the dose-dependent effects of sorafenib on the immune response, which is related to nuclear factor of activated T cells 1 (NFAT1) activity. In vitro and in vivo experiments...

Descripción completa

Detalles Bibliográficos
Autores principales: Iyer, Renuka V., Maguire, Orla, Kim, Minhyung, Curtin, Leslie I., Sexton, Sandra, Fisher, Daniel T., Schihl, Sarah A., Fetterly, Gerald, Menne, Stephan, Minderman, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562672/
https://www.ncbi.nlm.nih.gov/pubmed/31100868
http://dx.doi.org/10.3390/cancers11050681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562672/
https://www.ncbi.nlm.nih.gov/pubmed/31100868
http://dx.doi.org/10.3390/cancers11050681

Ejemplares similares